NEOJENBIO is a biotechnology company, established in 2025 with a clear vision: to become a global leader in the development, manufacturing, and distribution of high-quality, ethically sourced human hepatocytes. These specialized liver cells are indispensable for a wide range of biomedical applications, including drug metabolism studies, toxicity screening, regenerative medicine, and basic research. With drug discovery pipelines expanding worldwide and regulatory agencies demanding more accurate preclinical testing, the demand for reliable hepatocytes has never been greater. Yet, the global supply chain remains fragmented, expensive, and inconsistent, leaving a critical gap that NEOJENBIO is uniquely positioned to fill.